JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2007; 49:2274-2282, doi:10.1016/j.jacc.2007.02.051 (Published online 24 May 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Böger, G. I.
Right arrow Articles by Böger, R. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Böger, G. I.
Right arrow Articles by Böger, R. H.

Asymmetric Dimethylarginine Determines the Improvement of Endothelium-Dependent Vasodilation by Simvastatin

Effect of Combination With Oral L-Arginine

Gerhild I. Böger, PhD*, Tanja K. Rudolph, MD*,{dagger}, Renke Maas, MD*, Edzard Schwedhelm, PhD*, Ekaterina Dumbadze*, Anneke Bierend*, Ralf A. Benndorf, MD* and Rainer H. Böger, MD*,*

* Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology, Hamburg, Germany
{dagger} Department of Cardiology, University Heart Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.


Figure 1
View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Distribution of Circulating ADMA Concentrations

(A) Distribution of circulating asymmetric dimethylarginine (ADMA) concentrations in a cohort of 98 clinically healthy ambulatory subjects. Vertical lines indicate the median (solid line), which was 0.39 µmol/l, and the 25th and 75th percentiles (dashed lines; 0.35 µmol/l and 0.48 µmol/l, respectively). (B) Asymmetric dimethylarginine levels in study participants. Mean and SD in the 2 groups are marked by a horizontal bar and vertical line, respectively. Each subject is represented by a circle. In panel B, filled circles indicate subjects with high ADMA and unfilled circles indicate subjects with low ADMA.

 

Figure 2
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Effects of Simvastatin, L-Arginine, and Their Combination on Endothelium-Dependent and -Independent Vasodilation in Subjects With High ADMA

Endothelium-dependent (A) and endothelium-independent vasodilation (B) in the brachial artery as assessed by high-resolution ultrasound before and after 3 weeks of treatment with simvastatin, L-arginine sustained release (SR), or their combination, in subjects with elevated asymmetric dimethylarginine (ADMA) concentration. *p < 0.05 versus baseline or between groups as indicated. Hatched bars = before treatment; black bars = after treatment. GTN = nitroglycerin; n.s. = not significant.

 

Figure 3
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 Effects of Simvastatin, L-Arginine, and Their Combination on Endothelium-Dependent and -Independent Vasodilation in Subjects With Low ADMA

Endothelium-dependent (A) and endothelium-independent vasodilation (B) in the brachial artery as assessed by high-resolution ultrasound before and after 3 weeks of treatment with simvastatin, L-arginine SR, or their combination, in subjects with low-normal ADMA concentration. *p < 0.05 versus baseline or between groups as indicated. Hatched bars = before treatment; black bars = after treatment. Abbreviations as in Figure 2.

 

Figure 4
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4 Relationship Between Plasma ADMA Concentration and the Endothelial Response to Simvastatin

Filled circles = subjects with high ADMA; unfilled circles = subjects with low ADMA. ADMA = asymmetric dimethylarginine; FMD = flow-mediated dilation.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.